bioxcell-mpd-l1 Search Results


mpd l1  (Bio X Cell)
96
Bio X Cell mpd l1
Anti-PD1 and anti-PDL1 antibodies abrogate the anti-GVHD effect of targeted mutation of Hif1a in donor T cells (A) Diagram of the experimental scheme. BALB/c mice received 5 × 10 6 CD45.1 T cell-depleted BM cells + 5 × 10 5 WT or Hif1a −/− T cells. WT and KO T cell recipients were divided to receive treatment with anti-mouse PDL1 <t>(10F.9G2),</t> anti-mouse PD1 (RMP1-14), or isotype control immunoglobulin G (IgG) antibodies (vehicle), as detailed in the . (B) Kaplan-Meier survival curves are shown for the six groups of mice (n = 10–13 mice per group). The data are representative of three experiments. (C) H&E-stained tissues are shown in representative images for each of six groups of mice, highlighting major pathological findings. (D) Summary of histological scoring for the organs in each group depicted in (C). Scoring criteria are described in the . (E) Representative immunofluorescence staining for CD3 and PDL1 in the liver and salivary gland (S.G.) tissues from mice receiving different treatments. (F and G) Representative immunofluorescence images are shown for liver, lung, intestine, skin, and tongue sections from WT or Hif1a −/− T cell recipients. Co-staining of CD3 and PDL1 is shown in (F), and co-staining of CD3 and cleaved caspase-3 (cCasp3) is shown in (G).
Mpd L1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mpd l1/product/Bio X Cell
Average 96 stars, based on 1 article reviews
mpd l1 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

Image Search Results


Anti-PD1 and anti-PDL1 antibodies abrogate the anti-GVHD effect of targeted mutation of Hif1a in donor T cells (A) Diagram of the experimental scheme. BALB/c mice received 5 × 10 6 CD45.1 T cell-depleted BM cells + 5 × 10 5 WT or Hif1a −/− T cells. WT and KO T cell recipients were divided to receive treatment with anti-mouse PDL1 (10F.9G2), anti-mouse PD1 (RMP1-14), or isotype control immunoglobulin G (IgG) antibodies (vehicle), as detailed in the . (B) Kaplan-Meier survival curves are shown for the six groups of mice (n = 10–13 mice per group). The data are representative of three experiments. (C) H&E-stained tissues are shown in representative images for each of six groups of mice, highlighting major pathological findings. (D) Summary of histological scoring for the organs in each group depicted in (C). Scoring criteria are described in the . (E) Representative immunofluorescence staining for CD3 and PDL1 in the liver and salivary gland (S.G.) tissues from mice receiving different treatments. (F and G) Representative immunofluorescence images are shown for liver, lung, intestine, skin, and tongue sections from WT or Hif1a −/− T cell recipients. Co-staining of CD3 and PDL1 is shown in (F), and co-staining of CD3 and cleaved caspase-3 (cCasp3) is shown in (G).

Journal: Cell Reports Medicine

Article Title: Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease

doi: 10.1016/j.xcrm.2023.101236

Figure Lengend Snippet: Anti-PD1 and anti-PDL1 antibodies abrogate the anti-GVHD effect of targeted mutation of Hif1a in donor T cells (A) Diagram of the experimental scheme. BALB/c mice received 5 × 10 6 CD45.1 T cell-depleted BM cells + 5 × 10 5 WT or Hif1a −/− T cells. WT and KO T cell recipients were divided to receive treatment with anti-mouse PDL1 (10F.9G2), anti-mouse PD1 (RMP1-14), or isotype control immunoglobulin G (IgG) antibodies (vehicle), as detailed in the . (B) Kaplan-Meier survival curves are shown for the six groups of mice (n = 10–13 mice per group). The data are representative of three experiments. (C) H&E-stained tissues are shown in representative images for each of six groups of mice, highlighting major pathological findings. (D) Summary of histological scoring for the organs in each group depicted in (C). Scoring criteria are described in the . (E) Representative immunofluorescence staining for CD3 and PDL1 in the liver and salivary gland (S.G.) tissues from mice receiving different treatments. (F and G) Representative immunofluorescence images are shown for liver, lung, intestine, skin, and tongue sections from WT or Hif1a −/− T cell recipients. Co-staining of CD3 and PDL1 is shown in (F), and co-staining of CD3 and cleaved caspase-3 (cCasp3) is shown in (G).

Article Snippet: Antibodies for hCD3 (NBP1, Novus), mCD3 (SP7, abcam), cleaved caspase-3 (Asp175, 5A1E), and mPD-L1 (10F.9G2, BioxCell, West Lebanon, NH) were used for immunofluorescence.

Techniques: Mutagenesis, Staining, Immunofluorescence

Journal: Cell Reports Medicine

Article Title: Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease

doi: 10.1016/j.xcrm.2023.101236

Figure Lengend Snippet:

Article Snippet: Antibodies for hCD3 (NBP1, Novus), mCD3 (SP7, abcam), cleaved caspase-3 (Asp175, 5A1E), and mPD-L1 (10F.9G2, BioxCell, West Lebanon, NH) were used for immunofluorescence.

Techniques: Recombinant, Software